PHG, IBRX and MESO are among premarket gainers
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 29 2024
0mins
Should l Buy IBRX?
Source: SeekingAlpha
- Gainers: Various companies experienced significant stock gains, including Deciphera Pharmaceuticals, Koninklijke Philips, ZyVersa Therapeutics, and others.
- FDA Clearance: NKGen Biotech announced FDA clearance of an Investigational New Drug (IND) application for SNK01 NK Cell Therapy in Parkinson’s Disease.
- Market Movement: Tesla's positive moment in China boosted Chinese electric vehicle stocks.
- Strategic Partnership: WISeKey International strengthened its partnership with the Swiss Armed Forces in the space sector, planning to launch an enhanced WISeSat satellite in Q3 2024 using SpaceX.
- Business Performance: Domino's Pizza saw a rally after reporting strong comparable sales growth in Q1.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IBRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IBRX
Wall Street analysts forecast IBRX stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 6.660
Low
5.00
Averages
7.33
High
9.00
Current: 6.660
Low
5.00
Averages
7.33
High
9.00
About IBRX
Immunitybio, Inc. is a vertically integrated, clinical-stage biotechnology company developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Using its applied science and platforms to treat cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies to reduce or eliminate the need for standard high-dose chemotherapy. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins, vaccine vectors, and cell therapies. Its biologic commercial product candidate, Anktiva, is an IL-15 superagonist antibody-cytokine fusion protein.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ImmunityBio's Global Expansion and Balance Sheet Strengthening
- Balance Sheet Strengthening: Founder Patrick Soon-Shiong indicated plans to strengthen the balance sheet and prepare for global expansion, despite recent stock price impacts from an FDA warning letter, the company is focused on achieving long-term growth.
- European Expansion Talks: Soon-Shiong mentioned discussions with a European health minister aimed at advancing 'immunotherapy 2.0', which will help the company promote NK cell and CD8 T-cell-based therapies in new markets, enhancing its competitive position.
- Declining Short Interest: Short interest in IBRX has decreased from 13.7% in mid-February to 12.9%, reflecting increased market confidence in the Anktiva therapy, especially after receiving conditional marketing authorization from the EU.
- FDA Warning Impact: Although the FDA issued a warning regarding Anktiva's promotional claims, leading to a short-term stock drop, the company is actively advancing clinical trials for new indications, demonstrating resilience and potential in the market.
See More
ImmunityBio Secures $75M Financing from Oberland Capital
- Financing Agreement Update: ImmunityBio announced a $75 million non-dilutive financing from Oberland Capital as part of an existing royalty interest purchase agreement, increasing total capital commitment to $375 million, thereby enhancing liquidity to support the development of its cancer therapy Anktiva.
- Royalty Terms Adjustment: The terms of the deal remain unchanged except for a slight increase in the royalty payback rate, which provides the company with some flexibility for future earnings without altering the royalty cap.
- Debt Reduction Strategy: Concurrently, ImmunityBio revealed that Nant Capital converted $25 million of an outstanding promissory note into equity, resulting in the issuance of 4.6 million shares to alleviate the debt burden associated with the $505 million promissory note due in December 2024, thereby strengthening the company's financial stability.
- Market Reaction Analysis: Despite facing an FDA warning regarding Anktiva advertisements, the market's response to the financing and debt management measures remains positive, reflecting investor confidence in the company's long-term growth potential.
See More
Notice of Class Action Lawsuit for ImmunityBio Shareholders
- Class Action Notice: The Gross Law Firm has issued a notice to shareholders of ImmunityBio, Inc. (NASDAQ:IBRX), encouraging those who purchased shares during the class period from January 19, 2026, to March 24, 2026, to contact the firm regarding potential lead plaintiff appointment.
- Allegations of False Statements: The complaint alleges that during the class period, defendants made materially false and/or misleading statements, particularly that Soon-Shion overstated Anktiva's capabilities, resulting in misleading information about ImmunityBio's business and prospects.
- Registration Deadline: Shareholders must register by May 26, 2026, to participate in the class action, and upon registration, they will receive updates throughout the lifecycle of the case, ensuring they stay informed on developments.
- Law Firm Credentials: The Gross Law Firm is a nationally recognized class action law firm committed to protecting investors' rights who have suffered losses due to deceit and illegal business practices, emphasizing the need for companies to adhere to responsible business practices.
See More
ImmunityBio Secures $75 Million Financing
- Financing Agreement Expansion: ImmunityBio has secured $75 million in non-dilutive financing under its existing Royalty Interest Purchase Agreement with Oberland Capital, raising the total committed capital to $375 million, significantly enhancing the company's financial strength to support future R&D.
- Debt Reduction: Nant Capital, LLC converted $25 million of the outstanding promissory note into 4.6 million shares of common stock, a move that not only reduces the company's overall debt burden but also boosts investor confidence, indicating an improvement in the company's financial condition.
- Stock Price Surge: Following the financing announcement, ImmunityBio's stock rose over 4% in premarket trading on Tuesday, reflecting the market's positive expectations regarding the company's financing capabilities and future developments, potentially attracting more investor interest.
- Strategic Investor Support: This financing and equity conversion demonstrate ongoing support from Executive Chairman Patrick Soon-Shiong, M.D., further solidifying the company's market position in the biopharmaceutical sector.
See More
ImmunityBio Secures $75 Million in Non-Dilutive Funding
- Funding Expansion: ImmunityBio has secured $75 million in non-dilutive financing under its existing Revenue Interest Purchase Agreement with Oberland Capital, increasing total committed capital to $375 million, thereby enhancing the company's financial flexibility to support global expansion.
- Debt Reduction: Simultaneously, Nant Capital converted $25 million of outstanding promissory notes into 4.6 million shares of common stock, significantly alleviating ImmunityBio's debt burden and further strengthening its balance sheet.
- Global Regulatory Approvals: ANKTIVA® has received approvals across five regulatory jurisdictions, covering approximately 34 countries, marking rapid international expansion for ImmunityBio and is expected to drive future sales growth.
- Strategic Development Outlook: This financing and debt conversion reflect strong confidence in ImmunityBio's strategy, supporting its leadership in immunotherapy and facilitating the development of next-generation immunotherapy treatments.
See More
ImmunityBio Faces Class Action Lawsuit
- Class Action Initiated: Bragar Eagel & Squire, P.C. has announced a class action lawsuit against ImmunityBio for investors who purchased securities between January 19, 2026, and March 24, 2026, indicating significant legal risks for the company.
- False Statement Allegations: The lawsuit alleges that ImmunityBio's executive Patrick Soon-Shiong materially overstated Anktiva's capabilities, leading to misleading statements about the company's business and prospects, which could result in investor losses.
- Investor Rights Protection: Investors must apply by May 26, 2026, to be appointed as lead plaintiff in the lawsuit, highlighting the legal process's role in protecting investor rights and potentially impacting the company's future stock performance.
- Law Firm Background: Bragar Eagel & Squire, P.C. is a nationally recognized law firm specializing in shareholder rights, focusing on securities and commercial litigation, demonstrating its expertise and influence in investor protection.
See More
ImmunityBio's Global Expansion and Balance Sheet Strengthening
- Balance Sheet Strengthening: Founder Patrick Soon-Shiong indicated plans to strengthen the balance sheet and prepare for global expansion, despite recent stock price impacts from an FDA warning letter, the company is focused on achieving long-term growth.
- European Expansion Talks: Soon-Shiong mentioned discussions with a European health minister aimed at advancing 'immunotherapy 2.0', which will help the company promote NK cell and CD8 T-cell-based therapies in new markets, enhancing its competitive position.
- Declining Short Interest: Short interest in IBRX has decreased from 13.7% in mid-February to 12.9%, reflecting increased market confidence in the Anktiva therapy, especially after receiving conditional marketing authorization from the EU.
- FDA Warning Impact: Although the FDA issued a warning regarding Anktiva's promotional claims, leading to a short-term stock drop, the company is actively advancing clinical trials for new indications, demonstrating resilience and potential in the market.
See More
ImmunityBio Secures $75M Financing from Oberland Capital
- Financing Agreement Update: ImmunityBio announced a $75 million non-dilutive financing from Oberland Capital as part of an existing royalty interest purchase agreement, increasing total capital commitment to $375 million, thereby enhancing liquidity to support the development of its cancer therapy Anktiva.
- Royalty Terms Adjustment: The terms of the deal remain unchanged except for a slight increase in the royalty payback rate, which provides the company with some flexibility for future earnings without altering the royalty cap.
- Debt Reduction Strategy: Concurrently, ImmunityBio revealed that Nant Capital converted $25 million of an outstanding promissory note into equity, resulting in the issuance of 4.6 million shares to alleviate the debt burden associated with the $505 million promissory note due in December 2024, thereby strengthening the company's financial stability.
- Market Reaction Analysis: Despite facing an FDA warning regarding Anktiva advertisements, the market's response to the financing and debt management measures remains positive, reflecting investor confidence in the company's long-term growth potential.
See More
Notice of Class Action Lawsuit for ImmunityBio Shareholders
- Class Action Notice: The Gross Law Firm has issued a notice to shareholders of ImmunityBio, Inc. (NASDAQ:IBRX), encouraging those who purchased shares during the class period from January 19, 2026, to March 24, 2026, to contact the firm regarding potential lead plaintiff appointment.
- Allegations of False Statements: The complaint alleges that during the class period, defendants made materially false and/or misleading statements, particularly that Soon-Shion overstated Anktiva's capabilities, resulting in misleading information about ImmunityBio's business and prospects.
- Registration Deadline: Shareholders must register by May 26, 2026, to participate in the class action, and upon registration, they will receive updates throughout the lifecycle of the case, ensuring they stay informed on developments.
- Law Firm Credentials: The Gross Law Firm is a nationally recognized class action law firm committed to protecting investors' rights who have suffered losses due to deceit and illegal business practices, emphasizing the need for companies to adhere to responsible business practices.
See More
ImmunityBio Secures $75 Million Financing
- Financing Agreement Expansion: ImmunityBio has secured $75 million in non-dilutive financing under its existing Royalty Interest Purchase Agreement with Oberland Capital, raising the total committed capital to $375 million, significantly enhancing the company's financial strength to support future R&D.
- Debt Reduction: Nant Capital, LLC converted $25 million of the outstanding promissory note into 4.6 million shares of common stock, a move that not only reduces the company's overall debt burden but also boosts investor confidence, indicating an improvement in the company's financial condition.
- Stock Price Surge: Following the financing announcement, ImmunityBio's stock rose over 4% in premarket trading on Tuesday, reflecting the market's positive expectations regarding the company's financing capabilities and future developments, potentially attracting more investor interest.
- Strategic Investor Support: This financing and equity conversion demonstrate ongoing support from Executive Chairman Patrick Soon-Shiong, M.D., further solidifying the company's market position in the biopharmaceutical sector.
See More
ImmunityBio Secures $75 Million in Non-Dilutive Funding
- Funding Expansion: ImmunityBio has secured $75 million in non-dilutive financing under its existing Revenue Interest Purchase Agreement with Oberland Capital, increasing total committed capital to $375 million, thereby enhancing the company's financial flexibility to support global expansion.
- Debt Reduction: Simultaneously, Nant Capital converted $25 million of outstanding promissory notes into 4.6 million shares of common stock, significantly alleviating ImmunityBio's debt burden and further strengthening its balance sheet.
- Global Regulatory Approvals: ANKTIVA® has received approvals across five regulatory jurisdictions, covering approximately 34 countries, marking rapid international expansion for ImmunityBio and is expected to drive future sales growth.
- Strategic Development Outlook: This financing and debt conversion reflect strong confidence in ImmunityBio's strategy, supporting its leadership in immunotherapy and facilitating the development of next-generation immunotherapy treatments.
See More
ImmunityBio Faces Class Action Lawsuit
- Class Action Initiated: Bragar Eagel & Squire, P.C. has announced a class action lawsuit against ImmunityBio for investors who purchased securities between January 19, 2026, and March 24, 2026, indicating significant legal risks for the company.
- False Statement Allegations: The lawsuit alleges that ImmunityBio's executive Patrick Soon-Shiong materially overstated Anktiva's capabilities, leading to misleading statements about the company's business and prospects, which could result in investor losses.
- Investor Rights Protection: Investors must apply by May 26, 2026, to be appointed as lead plaintiff in the lawsuit, highlighting the legal process's role in protecting investor rights and potentially impacting the company's future stock performance.
- Law Firm Background: Bragar Eagel & Squire, P.C. is a nationally recognized law firm specializing in shareholder rights, focusing on securities and commercial litigation, demonstrating its expertise and influence in investor protection.
See More
